Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living with Type 1 Diabetes

Last updated: February 24, 2025
Sponsor: Institut de Recherches Cliniques de Montreal
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Mellitus Types I And Ii

Diabetes And Hypertension

Diabetes Prevention

Treatment

Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment

Clinical Study ID

NCT06683391
2025-1295
  • Ages > 18
  • All Genders

Study Summary

The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at < 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults aged 18 years and older

  • Clinical diagnosis of Type 1 diabetes for at least 1 year

  • Currently treated with multiple daily insulin injections (MDI), continuoussubcutaneous insulin infusion (CSII), or automated insulin delivery (AID) systems

  • HbA1c level below 9.0%

  • Equal distribution of male and female participants, as well as MDI/CSII and AIDusers

Exclusion

Exclusion Criteria:

  • Gastroparesis

  • Significant cardiac rhythm abnormalities

  • Clinically significant microvascular complications such as nephropathy (eGFR < 40ml/min) or severe proliferative retinopathy

  • Diagnosis of epilepsy

  • Pregnancy or currently breastfeeding

  • Severe hypoglycemic episode within 1 month prior to inclusion

  • Macrovascular events or uncorrected hypokalemia (K+ < 3.5 mmol/L) within 3 monthsprior to inclusion

  • Anticipated treatment changes during the trial period

  • Inability to provide informed consent

Study Design

Total Participants: 32
Treatment Group(s): 1
Primary Treatment: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Phase:
Study Start date:
February 06, 2025
Estimated Completion Date:
December 31, 2027

Study Description

The REMODAL trial explores an individualized, proactive approach to treat mild hypoglycemia in individuals with Type 1 diabetes (T1D) who use CGM. Traditional guidelines, established in the 1980s, recommend the "15g/15min rule" - consuming 15g of CHO every 15 minutes for glucose levels below 4.0 mmol/L. However, these guidelines may no longer be optimal with the advancements in insulin therapies and CGM, which provide real-time glucose data and predict glucose trends.

In this study, 32 adult participants with T1D will receive three interventions to test different amounts and timing of CHO intake under real-life conditions. These are as follows:

  1. 8g of CHO at a threshold of 5.0 mmol/L (proactive approach).

  2. 16g of CHO at a threshold of 5.0 mmol/L (proactive approach).

  3. 16g of CHO at a threshold of < 4.0 mmol/L (traditional reactive approach).

The primary outcome is the prevention rate of hypoglycemic episodes under each intervention, with additional measures on glucose levels, time spent in hypoglycemia, and rebound hyperglycemia. The study also considers differences in glucose management between multiple daily injections, continuous subcutaneous insulin infusion, and automated insulin delivery systems, which may affect CHO needs. This study hopes to redefine effective hypoglycemia management in the modern era of diabetes care, providing personalized recommendations to improve glycemic control and overall quality of life.

Connect with a study center

  • Institut de recherches cliniques de Montréal

    Montreal, Quebec H2W 1R7
    Canada

    Active - Recruiting

  • Montreal Clinical Research Institute

    Montreal, Quebec H2W1R7
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.